Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (361-370 of 436) with videos related to

Pageof 44
Sort By:
Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
Blood|June 11, 2021
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaTomoyuki Tanaka, Kiyomi Morita, Sanam Loghavi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2017
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic SyndromeStefan O Ciurea, Mithun V Shah, Rima M Saliba, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|June 18, 2020
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortalityGhayas C Issa, Hagop M Kantarjian, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Frontiers in Immunology|October 16, 2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of conceptMuhammad Aminu, Naval Daver, Myrna C B Godoy, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Pageof 44

Showing results (361-370 of 436) with videos related to

Sort By:
Pageof 44
Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
Blood|June 11, 2021
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaTomoyuki Tanaka, Kiyomi Morita, Sanam Loghavi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2017
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic SyndromeStefan O Ciurea, Mithun V Shah, Rima M Saliba, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|June 18, 2020
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortalityGhayas C Issa, Hagop M Kantarjian, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Frontiers in Immunology|October 16, 2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of conceptMuhammad Aminu, Naval Daver, Myrna C B Godoy, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Pageof 44